FGF23 induces left ventricular hypertrophy
Robier Aguillon-Prada's research works | University of Miami Miller School of Medicine, Florida (UM) and other places
Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection.,Journal of the American College of Cardiology - X-MOL
1568636025 NPI Number | ROBIER A AGUILLON PRADA M.D. | CLEVELAND, OH | NPI Registry | Medical Coding Library | www.HIPAASpace.com © 2020
Robier A. Aguillon Prada, MD | Critical Care Medicine Doctor in Cleveland, OH
Cyclodextrin Protects Podocytes in Diabetic Kidney Disease
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical
Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk,Journal of the American College of Cardiology - X-MOL
Dr. Robier Aguillon Prada, MD – Cleveland, OH | Internal Medicine
Table 1 from FGF23 induces left ventricular hypertrophy. | Semantic Scholar
Robier Aguillon-Prada's research works | University of Miami Miller School of Medicine, Florida (UM) and other places
Robier Facebook, Twitter & MySpace on PeekYou
Dr. Robier Aguillon Prada, MD, Critical Care Medicine Specialist - Cleveland, OH | Sharecare
Dr. Robier Aguillon Prada, MD | Cleveland, OH | Healthgrades
Robier Facebook, Twitter & MySpace on PeekYou
Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis | Science Translational Medicine
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. - Abstract - Europe PMC
Robier Aguillon-Prada's research works | University of Miami Miller School of Medicine, Florida (UM) and other places
Aguillon Prada, Robier A Md Ohio,Cleveland, Doctors ,9500 Euclid Ave,44193 | 6194503179
Sesiones mensuales 2020 | Medicina interna
JCI - FGF23 induces left ventricular hypertrophy
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. - Abstract - Europe PMC
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical
Dr. Richard Glenn G. Aguilera - doctoryouneed.org %
Dr. Robier Aguillon Prada, MD | Cleveland, OH | Healthgrades
